Nymox Pharmaceutical Corporation is a leading biopharmaceutical company based in Hasbrouck Heights, NJ, dedicated to developing a groundbreaking therapy for men suffering from an enlarged prostate gland, known as Benign Prostate Hyperplasia (BPH). Their unique and innovative injectable therapy selectively targets the prostate gland cells, providing a safe, efficacious, and long-lasting solution.
With a team of experts behind Nymox Pharmaceuticals Corporation, ongoing research is focused on the development of Fexapotide, not only for BPH but also for low-grade localized prostate cancer. Recent scientific publications featuring Fexapotide Triflutate highlight the company's commitment to advancing medical knowledge in this field, while regular press releases keep shareholders and the public informed about their progress and achievements.
Generated from the website